Tobira Therapeutics, Inc. Increase (Decrease) in Accounts Payable and Accrued Liabilities
Tobira Therapeutics, Inc. reported Increase (Decrease) in Accounts Payable and Accrued Liabilities of $2.15 million for the 6-month period ending 2016-06-30, per its 10-Q filed 2016-08-09.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities · last filed 2016-08-09
- Tobira Therapeutics, Inc. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2016-06-30 was $744.00K, a 35.08% decline year-over-year.
- Tobira Therapeutics, Inc. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2016-03-31 was $1.40M, a 28.36% increase year-over-year.
- Tobira Therapeutics, Inc. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2015-12-31 was $2.29M, a 60.88% increase year-over-year.
- Tobira Therapeutics, Inc. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2015-09-30 was -$2.01M.
- Tobira Therapeutics, Inc. increase (decrease) in accounts payable and accrued liabilities for fiscal 2015 was $2.52M, a 11.54% decline from fiscal 2014.
- Tobira Therapeutics, Inc. increase (decrease) in accounts payable and accrued liabilities for fiscal 2014 was $2.85M.
- Tobira Therapeutics, Inc. increase (decrease) in accounts payable and accrued liabilities for fiscal 2013 was -$2.37M.
| Period end | Increase (Decrease) in Accounts Payable and Accrued Liabilities 3 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 6 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 9 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 12 month |
|---|---|---|---|---|
| 2016-06-30 | $744.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-09 | $2.15M 10-Q · filed 2016-08-09 | $4.44M derived: sum of 3 quarters · filed 2016-08-09 | $2.43M derived: sum of 4 quarters · filed 2016-08-09 |
| 2016-03-31 | $1.40M 10-Q · filed 2016-05-09 | $3.69M derived: sum of 2 quarters · filed 2016-05-09 | $1.69M derived: sum of 3 quarters · filed 2016-05-09 | $2.83M derived: sum of 4 quarters · filed 2016-08-09 |
| 2015-12-31 | $2.29M derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-03 | $284.00K derived: sum of 2 quarters · filed 2016-03-03 | $1.43M derived: sum of 3 quarters · filed 2016-08-09 | $2.52M 10-K · filed 2016-03-03 |
| 2015-09-30 | -$2.01M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-10 | -$861.00K derived: sum of 2 quarters · filed 2016-08-09 | $232.00K 10-Q · filed 2015-11-10 | $1.66M derived: sum of 4 quarters · filed 2016-08-09 |
| 2015-06-30 | $1.15M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-09 | $2.24M 10-Q · filed 2016-08-09 | $3.66M derived: sum of 3 quarters · filed 2016-08-09 | $3.23M derived: sum of 4 quarters · filed 2016-08-09 |
| 2015-03-31 | $1.09M 10-Q · filed 2016-05-09 | $2.52M derived: sum of 2 quarters · filed 2016-05-09 | $2.08M derived: sum of 3 quarters · filed 2016-05-09 | |
| 2014-12-31 | $1.42M derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-03 | $991.00K derived: sum of 2 quarters · filed 2016-03-03 | $2.85M 10-K · filed 2016-03-03 | |
| 2014-09-30 | -$433.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-10 | $1.43M 10-Q · filed 2015-11-10 | ||
| 2014-06-30 | $1.86M 10-Q · filed 2015-08-11 | |||
| 2013-12-31 | -$2.37M 10-K · filed 2016-03-03 |